Señales en vivo de IRLAB-A.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:29):

Stats
Volumen de hoy	55 957.00
Volumen promedio	77 758.00
Capitalización de mercado	587.80M
EPS	SEK0 ( 2024-02-06 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-08
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.31
ATR14	SEK0.0790 (0.70%)

Volumen Correlación

Largo: 0.11 (neutral)

Corto: -0.44 (neutral)

Signal:(50.813) Neutral

IRLAB Therapeutics AB Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IRLAB Therapeutics AB Correlación - Moneda/Commodity

-0.51
( weak negative )

-0.27
( neutral )

0.12
( neutral )

-0.41
( neutral )

0.18
( neutral )

-0.21
( neutral )

IRLAB Therapeutics AB Finanzas

Annual	2023
Ingresos:	SEK5.68M
Beneficio Bruto:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2023
Ingresos:	SEK5.68M
Beneficio Bruto:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2022
Ingresos:	SEK61.14M
Beneficio Bruto:	SEK-111.23M (-181.94 %)
EPS:	SEK-2.20

FY	2021
Ingresos:	SEK207.78M
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK0.494

Financial Reports:

No articles found.

IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.

Actualizaciones en tiempo real para IRLAB Therapeutics AB [IRLAB-A.ST]

Upcoming Earnings Alert